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A B S T R A C T
Alzheimer's disease (AD) is a neurodegenerative disease that is clinically characterized by progressive cognitive
decline. More than 200 pathogenic mutations have been identified in amyloid-β precursor protein (APP), presenilin
1 (PSEN1) and presenilin 2 (PSEN2). Additionally, common and rare variants occur within APP, PSEN1, and
PSEN2 that may be risk factors, protective factors, or benign, non-pathogenic polymorphisms. Yet, to date, no
single study has carefully examined the effect of all of the variants of unknown significance reported in APP,
PSEN1 and PSEN2 on Aβ isoform levels in vitro. In this study, we analyzed Aβ isoform levels by ELISA in a cell-
based system in which each reported pathogenic and risk variant in APP, PSEN1, and PSEN2 was expressed
individually. In order to classify variants for which limited family history data is available, we have implemented
an algorithm for determining pathogenicity using available information from multiple domains, including ge-
netic, bioinformatic, and in vitro analyses. We identified 90 variants of unknown significance and classified 19 as
likely pathogenic mutations. We also propose that five variants are possibly protective. In defining a subset of
these variants as pathogenic, individuals from these families may eligible to enroll in observational studies and
clinical trials.
1. Introduction
Alzheimer's disease (AD) is characterized clinically by progressive
cognitive decline and neuropathologically by progressive neuronal loss
and the accumulation of amyloid plaques and neurofibrillary tangles.
Mutations in amyloid-β precursor protein (APP), presenilin 1 (PSEN1)
and presenilin 2 (PSEN2) are the pathogenic cause of autosomal
dominant AD (ADAD). Rare recessive mutations in APP (A673V and
E693Δ) also cause early onset AD (Di Fede et al., 2009; Giaccone et al.,
2010; Tomiyama et al., 2008).
While more than 200 pathogenic mutations have been identified in
APP, PSEN1, or PSEN2, more than 90 additional variants have been
identified where the pathogenicity remains in question (reviewed in
(Karch et al., 2014; Cruts et al., 2012)). The uncertainty in pathogenicity
may be due to several reasons. In some cases, variants in APP, PSEN1 or
PSEN2 have been identified in families with several generations of AD. In
these cases, pathogenicity can be evaluated by segregation analysis: the
presence of the variant in multiple individuals with clinically or patholo-
gically confirmed AD and the absence of the variant in healthy, older fa-
mily members. However, in many cases only the single proband has DNA
available. Alternatively, there may be limited or no family history. Chal-
lenges also arise when young, healthy individuals are found to be variant
carriers. To assess the pathogenicity of novel variants in APP, PSEN1, and
PSEN2 when pedigree and clinical data is limited or incomplete, Guerreiro
and colleagues (Guerreiro et al., 2010a) proposed a pathogenicity algo-
rithm. We have since modified and expanded this algorithm to evaluate
pathogenicity of six novel variants identified through the Dominantly In-
herited Alzheimer Network Extended Registry (DIAN-EXR) using genetic,
biochemical, biomarker, and clinical data (Hsu et al., 2018). In our
modified algorithm, we found that biochemical evidence of a change in Aβ
was informative in assessing pathogenicity where genetic data was limited
(Hsu et al., 2018).
To date, more than 90 variants of unknown significance are in-
cluded in genetic databases for Alzheimer's disease (AD/FTD database
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and AlzForum Mutations database), in part due to the reliance on ge-
netic information alone for classification of pathogenicity (Cruts et al.,
2012). Here, we further modified our pathogenicity algorithm to clas-
sify 90 variants of unknown significance for which no family segrega-
tion data is available that have been previously reported in the AD/FTD
and AlzForum Mutations Databases.
2. Material and methods
2.1. Identification of variants of unknown significance
To identify variants of unknown significance, we queried the AD/
FTD ((5)http://www.molgen.ua.ac.be/ADMutations/) and AlzForum
Mutations Databases (https://www.alzforum.org/mutations). Variants
classified by the Guerreiro et al. algorithm (Guerreiro et al., 2010a) as
being “not pathogenic” or “pathogenic nature unclear” were selected
for evaluation by bioinformatic and in vitro analyses (n = 90; Supple-
mental Table 1).
2.2. Bioinformatics
To determine whether APP, PSEN1, and PSEN2 variants represented
rare or common polymorphisms, we investigated two population-based
exome sequencing databases: Exome Variant Server (EVS) and Exome
Aggregation Consortium (ExAC) browser. The Genome Aggregation
Database (gnomAD) was excluded from this study given that sequen-
cing data from the Alzheimer's Disease Sequencing Project are included
in the database and thus would not be representative of a control po-
pulation. Polymorphism phenotype v2 (PolyPhen-2; (Adzhubei et al.,
2010)) and Sorting Intolerant From Tolerant (SIFT) were used to pre-
dict whether the amino acid change would be disruptive to the encoded
protein.
2.3. In vitro analyses
2.3.1. Plasmids and mutagenesis
The full-length APP cDNA (isoform 695) was cloned into pcDNA3.1
(Wang et al., 2004). APP variants (Table 1) were introduced into the
APP cDNA using a QuikChange Lightning Site-Directed Mutagenesis Kit
(Agilent Technologies, Santa Clara, CA, USA). Clones were sequenced to
confirm the presence of the variant and the absence of additional
modifications. APP wild-type (WT) and pathogenic APP KM670/671NL,
APP L723P and APP K724N mutations were included as controls. Three
variants were not generated due to incompatibility with the cDNA
plasmid: APP E296K, APP P299L, APP IVS17 83-88delAAGTAT, APP c
*18C>T, and APP c *372 A>G (N/A; Table 1).
The full-length PSEN1 cDNA was cloned into pcDNA3.1 myc/his
vector (Brunkan et al., 2005). PSEN1 variants (Table 1) were introduced
into the PSEN1 cDNA and screened as described above. PSEN1 WT and
pathogenic PSEN1 A79V, PSEN1 L286V, and PSEN1 exon 9 deletion
(ΔE9) mutations were included as controls. One variant was not gen-
erated due to incompatibility with the cDNA plasmid: PSEN1 N32N.
Four additional variants failed at the mutagenesis step and were not
modeled in the cellular assay: PSEN1 L219R, PSEN1 D333G, PSEN1
T354I, and PSEN1 S365Y (N/A; Table 1).
The full-length PSEN2 cDNA was cloned into pcDNA3.1 vector
(Kovacs et al., 1996). PSEN2 variants (Table 1) were introduced into the
PSEN2 cDNA and screened as described above. PSEN2 WT and the
pathogenic PSEN2 N141I mutation were included as controls (Walker
et al., 2005). Nine variants failed at the mutagenesis step and were not
modeled in the cellular assay: PSEN2 T18M, PSEN2 R29H, PSEN2
V101M, PSEN2 S130L, PSEN2 H162N, PSEN1 V214L, PSEN2 T301M,
PSEN2 K306fs, and PSEN2 P334R (N/A; Table 1).
In total, we generated 65 plasmids containing variants of unknown
significance in APP, PSEN1 or PSEN2.
2.3.2. Transient transfection
To assess APP variants, we transiently expressed APP WT, variant,
or mutant APP in mouse neuroblastoma cells (N2A). To assess PSEN1
and PSEN2 variants, we used mouse neuroblastoma cells in which en-
dogenous Psen1 and Psen2 were knocked out by CRISPR/Cas9 (N2A-
PS1/PS2 KO; Pimenova and Goate, 2020). We then transiently ex-
pressed human APP WT (695 isoform) along with the PSEN1 or PSEN2
constructs. N2A cells were maintained in equal amounts of Dulbecco's
modified Eagle's medium and Opti-MEM, supplemented with 5% fetal
bovine serum, 2 mM L-glutamine, and 100 μg/mL penicillin/strepto-
mycin. Upon reaching confluency, cells were transiently transfected
with Lipofectamine 2000 (Life Technologies). Culture media was re-
placed after 24 h, and cells were incubated for another 24 h prior to
analysis of extracellular Aβ in the media. Three independent transfec-
tions were performed for each construct and used for subsequent ana-
lyses. Six variants exhibited low expression levels when transiently
expressed and thus were not included in the Aβ ELISA analyses: APP
H677R, APP G709S, PSEN1 H163P, PSEN2 L143H, PSEN2 A237V and
PSEN2 A377V (N/A; Table 1).
2.3.3. Aβ Enzyme-linked immunosorbent assay (ELISA)
Conditioned media was collected and centrifuged at 3000 ×g at 4 °C
for 10 min to remove cell debris. Levels of Aβ40 and Aβ42 in cell
culture media were measured by sandwich ELISA as directed by the
manufacturer (Life Technologies, Carlsbad, CA, USA). Statistical dif-
ference was measured using a one-way ANOVA and post-hoc Dunnett
test.
2.3.4. Immunoblotting
Cell pellets were extracted on ice in lysis buffer (50 mM Tris pH 7.6,
2 mM EDTA, 150 mM NaCl, 1% NP40, 0.5% Triton 100×, protease
inhibitor cocktail) and centrifuged at 14,000 ×g. Protein concentration
was measured by BCA method as described by the manufacturer
(Pierce-Thermo). Standard SDS-PAGE was performed in 4–20%
Criterion TGX gels (Bio-Rad). Samples were boiled for 5 min in Laemmli
sample buffer prior to electrophoresis (Laemmli, 1970). Immunoblots
were probed with 22C11 (1:1000; Millipore) and goat-anti-rabbit-HRP
(1:5000; Thermo Fisher).
3. Results and discussion
3.1. The impact of variants of unknown significance in APP, PSEN1 and
PSEN2 on Aβ levels in vitro
Prior cellular studies have largely focused on defining the impact of
known pathogenic mutations in APP, PSEN1, and PSEN2 on extra-
cellular Aβ40 and Aβ42 levels (Haass et al., 1994; Haass et al., 1995;
Sun et al., 2017). Many common and rare variants occur within APP,
PSEN1, and PSEN2 that may be risk factors, protective factors, or be-
nign, non-pathogenic polymorphisms (Cruchaga et al., 2012; Sassi
et al., 2014). Yet, to date, no single study has systematically examined
the impact of these variants of unknown significance on Aβ isoform
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Table 1
APP, PSEN1 and PSEN2 variants of unknown significance evaluated by the pathogenicity algorithm.











APP A201V Yes N/A No Benign No Not pathogenic
APP A235V Yes N/A No Benign No Not pathogenic
APP D243N Yes N/A No Benign No Not pathogenic
APP E246K No N/A No Possibly damaging No Risk factor
APP E296K No N/A No Probably damaging N/A Probable pathogenic; Risk
factor
APP P299L No N/A No Probably damaging N/A Probable pathogenic; Risk
factor
APP V340M No N/A No Probably damaging No Not pathogenic
APP R468H No N/A No Probably damaging No Not pathogenic
APP A479S Yes N/A No Benign No Not pathogenic
APP K496Q No N/A No Probably damaging No Not pathogenic
APP A500T No N/A No Probably damaging No Not pathogenic
APP K510N No N/A No Probably damaging No Not pathogenic
APP Y538H No N/A No Possibly damaging No Not pathogenic; Possibly
protective
APP V562I No N/A No Benign No Not pathogenic
APP E599K Yes N/A No Probably damaging No Not pathogenic
APP T600M Yes N/A No Probably damaging No Not pathogenic
APP S614G Yes N/A No Benign Yes Risk factor
APP P620A No N/A No Possibly damaging Yes Probable pathogenic
APP P620L No N/A No Probably damaging Yes Probable pathogenic
APP E665D No N/A No Benign No Not pathogenic
APP A673T Yes N/A Yes Benign No Not pathogenic; Possibly
protective
APP H677R No N/A No Possibly damaging N/A Probable pathogenic; Risk
factor
APP G708G Yes N/A No N/A Yes Risk factor
APP G709S Yes N/A No Probably damaging N/A Not pathogenic; Risk factor
APP A713T Yes N/A No Probably damaging Yes Risk factor
APP A713V Yes N/A No Probably damaging No Not pathogenic; Possibly
protective
APP H733P No N/A No Probably damaging Yes Probable pathogenic
APP IVS17 83-88delAAGTAT No N/A No N/A N/A Unknown
APP c *18C>T No N/A No N/A N/A Unknown
APP c *372 A>G No N/A No N/A N/A Unknown
PSEN1 N32N No No No N/A N/A Not pathogenic
PSEN1 R35Q Yes No No Benign No Not pathogenic
PSEN1 D40del Yes Yes No N/A Yes Risk factor
PSEN1 E69D No No No Benign Yes Probable pathogenic
PSEN1 M84V No Yes Yes Probably damaging Yes Probable pathogenic
PSEN1 T99A No Yes No Probably damaging Yes Probable pathogenic
PSEN1 R108Q No No No Benign Yes Probable pathogenic
PSEN1 QR127G No Yes No N/A Yes Probable pathogenic
PSEN1 H131R No No No Benign Yes Probable pathogenic
PSEN1 M146V No Yes Yes Probably damaging Yes Probable pathogenic
PSEN1 H163P No Yes Yes Probably damaging N/A Probable pathogenic; Risk
factor
PSEN1 I168T No No No Benign No Not pathogenic
PSEN1 F175S No Yes No Probably damaging No Not pathogenic
PSEN1 F176L No No No Benign No Not pathogenic
PSEN1 V191A No Yes No Possibly damaging No Not pathogenic; Possibly
protective
PSEN1 L219R No Yes Yes Probably damaging N/A Probable pathogenic; Risk
factor
PSEN1 E318G Yes Yes No Benign No Not pathogenic
PSEN1 D333G Yes No No Possibly damaging N/A Not pathogenic
PSEN1 R352C Yes No No Possibly damaging No Not pathogenic
PSEN1 InsR352 No No No N/A N/A Unknown
PSEN1 T354I No No No Probably damaging N/A Probable pathogenic; Risk
factor
PSEN1 R358Q No Yes No Probably damaging Yes Probable pathogenic
PSEN1 S365Y No No No Possibly damaging N/A Probable pathogenic; Risk
factor
PSEN1 G378fs No Yes Yes N/A Yes Probable pathogenic
PSEN1 A396T No No Yes Probably damaging Yes Probable pathogenic
PSEN1 I439V No Yes Yes Benign Yes Probable pathogenic
PSEN2 T18M Yes No No Probably damaging N/A Probable pathogenic; Risk
factor
PSEN2 R29H No No No Probably damaging N/A Probable pathogenic; Risk
factor
PSEN2 G34S Yes No No Benign No Not pathogenic
PSEN2 R62C Yes Yes No Possibly damaging No Not pathogenic
(continued on next page)
S. Hsu, et al. Neurobiology of Disease 139 (2020) 104817
3
levels in vitro. The goal of this study was to determine the extent to
which variants in APP, PSEN1 and PSEN2 impact Aβ isoform levels and
to determine the utility of our assay to discriminate between pathogenic
and non-pathogenic variants.
We compared extracellular Aβ40, Aβ42, and Aβ42/40 in the media
of mouse N2A cells expressing APP WT, pathogenic APP mutations
(KM670/671NL, L723P or K724N) or APP containing one of 22 variants
of unknown significance (Fig. 1). We found that four of the 22 APP
variants resulted in a significant increase in the Aβ42/40 ratio com-
pared with APP WT: APP S614G, APP P620A, APP A713T, and APP
T719N (Fig. 1; Supplemental Table 2). APP T719N was a variant of
unknown significance that has recently been classified as pathogenic
(Hsu et al., 2018). Consistent with the reported effects of APP KM670/
671NL, we found that one APP variant (APP P620L) produced a sig-
nificant increase in Aβ40 and Aβ42 without altering the Aβ42/40 ratio
(Fig. 1C; Supplemental Table 2). Two APP variants resulted in a sig-
nificant increase in Aβ42 without significantly altering the Aβ42/40
ratio: APP G708G and APP H733P (Fig. 1; Supplemental Table 2). Those
variants that significantly increased the Aβ42/40 ratio or Aβ40 and
Aβ42 occur in the juxtamembrane region or amyloid beta domain
consistent with known pathogenic mutations; however, some variants,
including APP S614G, APP P620L, and APP P620A, occur outside of the
regions that are routinely sequenced (Fig. 1A) (Cruts et al., 2012).
To evaluate variants of unknown significance in PSEN1 and PSEN2,
we selected a cell line in which APP is metabolized similarly to neu-
ronal cells and in which endogenous presenilin genes are absent in
order to avoid background Aβ production: N2A-PS1/PS2 KO. The ab-
sence of endogenous Psen1 and Psen2 allows us to capture effects of
known pathogenic mutations in these genes, where a robust reduction
in Aβ40 results in a shift in the Aβ42/40 ratio. We evaluated 19 var-
iants in PSEN1 and 22 variants in PSEN2 (Figs. 2 and 3). Aβ40, Aβ42,
and Aβ42/40 levels were compared to PSEN1 WT or PSEN2 WT, re-
spectively. Six of the 19 PSEN1 variants resulted in a significant in-
crease in the Aβ42/40 ratio: PSEN1 M84V, PSEN1 T99A, PSEN1
QR127G, PSEN1 H131R, PSEN1 M146V, and PSEN1 G378fs (Fig. 2;
Supplemental Table 2). Six variants resulted in a significant increase in
Aβ40 and Aβ42 or Aβ42 only compared with PSEN1 WT: PSEN1 D40∆,
PSEN1 E69D, PSEN1 R108Q, PSEN1 R358Q, PSEN1 A396T, and PSEN1
I439V (Fig. 2; Supplemental Table 2). We found that six of 22 PSEN2
variants resulted in a significant increase in the Aβ42/40 ratio: PSEN2
P123L, PSEN2 I235F, PSEN2 L238F, PSEN2 R284G, PSEN2 P348L, and
PSEN2 D439A (Fig. 3; Supplemental Table 2). We evaluated several
known polymorphisms in PSEN2 that do not cause AD: PSEN2 R62H
and PSEN2 R71W (Walker et al., 2005). Cells expressing these benign
variants failed to produce a significant change in Aβ40 or Aβ42 (Fig. 3).
Overall, variants of unknown significance in PSEN1 and PSEN2 that
Table 1 (continued)











PSEN2 R62H Yes Yes No Benign No Not pathogenic
PSEN2 P69A Yes Yes No Benign No Not pathogenic
PSEN2 R71W Yes Yes No Benign No Not pathogenic
PSEN2 K82R No Yes No Probably damaging No Risk factor
PSEN2 A85V No Yes No Probably damaging No Risk factor
PSEN2 V101M No Yes No Probably damaging N/A Not pathogenic; Risk factor
PSEN2 P123L No Yes No Probably damaging Yes Probable pathogenic
PSEN2 E126fs No Yes Yes N/A No Risk factor
PSEN2 S130L Yes No No Possibly damaging N/A Not pathogenic; Risk factor
PSEN2 V139M Yes No No Possibly damaging No Not pathogenic
PSEN2 L143H No No No Probably damaging N/A Not pathogenic
PSEN2 R163H No No No Probably damaging No Not Pathogenic
PSEN2 H162N Yes No No Probably damaging N/A Not pathogenic; Risk factor
PSEN2 M174V No No No Benign No Not pathogenic
PSEN2 V214L Yes Yes No Probably damaging N/A Not pathogenic; Risk factor
PSEN2 I235F No Yes No Probably damaging Yes Probable pathogenic
PSEN2 A237V Yes Yes No Probably damaging N/A Not pathogenic; Risk factor
PSEN2 L238F No Yes No Probably damaging Yes Probable pathogenic
PSEN2 A252T Yes Yes No Possibly damaging No Not pathogenic; Possibly
protective
PSEN2 A258V No No No Benign No Not pathogenic
PSEN2 R284G No Yes No Probably damaging Yes Probable pathogenic
PSEN2 T301M Yes No No Possibly damaging N/A Not pathogenic; Risk factor
PSEN2 K306fs No No No N/A N/A Unknown
PSEN2 P334A No No No Benign No Not pathogenic
PSEN2 P334R Yes No No Benign N/A Not pathogenic
PSEN2 P348L No No No Benign Yes Probable pathogenic
PSEN2 A377V Yes Yes No Probably damaging N/A Not pathogenic
PSEN2 V393M Yes Yes No Probably damaging No Not pathogenic
PSEN2 T421M No Yes No Probably damaging No Not pathogenic
PSEN2 D439A Yes Yes No Probably damaging Yes Risk factor
a Benign, assigned by PolyPhen to mean not damaging.
b N/A, cell-based data not available (see Materials and Methods).
c Unknown indicates there is not sufficient functional/bioinformatic evidence to assign pathogenicity. Two assignments are made when functional/bioinformatic
data is not complete.
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alter Aβ were located across the gene. Thus, leveraging multiple types
of data (genetic, bioinformatic, and cellular) are most informative in
evaluating variants of unknown significance.
While the pathogenicity algorithm is designed to discriminate be-
tween pathogenic and non-pathogenic variants, by utilizing the in vitro
assay, we have the opportunity to discriminate between benign, non-
pathogenic variants and those that may confer resilience to AD. A rare
variant in APP, APP A673T, has been reported to confer protection
against AD risk (Jonsson et al., 2012; Maloney et al., 2014). In vitro,
APP A673T results in a significant reduction of Aβ42 and Aβ40 without
altering total APP levels by decreasing BACE activity (Maloney et al.,
2014). Interestingly, we observed that eight variants in APP, PSEN1,
and PSEN2 produced significantly lower levels of Aβ42 and Aβ40
(Figs. 1–3; Supplemental Table 2) without altering total APP levels: APP
A235V; APP Y538H; APP V713V; PSEN1 V191A; PSEN1 G378fs; PSEN2
E126fs; PSEN2 A252T; PSEN2 V393M (Fig. 4). Thus, we propose that
these variants may reduce Aβ production and confer resilience to AD.
3.2. Pathogenicity
Evaluating pathogenicity of variants of unknown significance re-









































































































































































































































Fig. 1. Impact of APP variants of unknown significance on Aβ levels in vitro. A. Diagram of the location of variants of unknown significance in APP. B–C. Mouse
N2A cells were transiently transfected with plasmids containing APP695 WT, known pathogenic mutations (K670N/M671L, L723P, K724N), or a variant of unknown
significance. After 48 h, media was collected and analyzed for Aβ42 and Aβ40 by ELISA. B. Ratio of Aβ42/40 expressed relative to APP WT. C. Aβ42 (white box) and
Aβ40 (gray box) levels expressed relative to APP WT. Graphs represent mean ± standard error of the mean (SEM). Significance indicated by Dunnett's t-test (*,
p < .05). Red, known pathogenic mutations. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this
article.)
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along with bioinformatic predictions and functional analyses. By eval-
uating more than 90 variants of unknown significance in vitro, we found
that only a subset of variants were able to significantly alter Aβ40,
Aβ42, or Aβ42/40 in a manner consistent with known pathogenic
mutations. Thus, we propose that the impact of variants on extracellular
Aβ levels in vitro should be weighed separately in the pathogenicity
algorithm. As such, we have revised the pathogenicity algorithm for use
when segregation data is unavailable (Fig. 5).
Applying this modified pathogenicity algorithm to the 90 variants of
unknown significance, we classified 19 variants as probably pathogenic
(APP P620A; APP P620L; APP H733P; PSEN1 E69D; PSEN1 M84V;
PSEN1 T99A; PSEN1 R108Q; PSEN1 QR127G; PSEN1 H131R; PSEN1
M146V; PSEN1 R358Q; PSEN1 G378fs; PSEN1 A396T; PSEN1 I439V;
PSEN2 P123L; PSEN2 I235F; PSEN2 L238F; PSEN2 R284G; PSEN2
P348L; Table 1). Many of the variants of unknown significance were
identified in single individuals presenting clinically with AD (Guerreiro
et al., 2010a; Hsu et al., 2018; Sassi et al., 2014; Nicolas et al., 2016;
Guerreiro et al., 2010b; Ikeda et al., 2013; Dobricic et al., 2012;
Rogaeva et al., 2001; Lohmann et al., 2012; Blauwendraat et al., 2016).





























































































































































































Fig. 2. Impact of PSEN1 variants of unknown significance on Aβ levels in vitro. A. Diagram of the location of variants of unknown significance in PSEN1. B–C.
Mouse N2A-PS1/PS2 KO cells were transiently transfected with plasmids containing APP WT and PSEN1 WT, known pathogenic mutations (A79V, L286V, and ΔE9),
or a variant of unknown significance. After 48 h, media was collected and analyzed for Aβ42 and Aβ40 by ELISA. B. Ratio of Aβ42/40 expressed relative to PSEN1
WT. C. Aβ42 (white box) and Aβ40 (gray box) levels expressed relative to PSEN1 WT. Graphs represent mean ± SEM. Significance indicated by Dunnett's t-test (*,
p < .05). Red, known pathogenic mutations. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this
article.)
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and Aβ42 levels (Figs. 1C, 2C, 3C). Among these variants, four variants
were identified in individuals with AD (Supplemental Table 1), while
five variants were identified in individuals with no evidence of neuro-
degeneration (APP Y538H, APP A673T, APP A713V, PSEN1 V191A,
PSEN2 A252T; Table 1). Thus, we predict that these five variants confer
resilience to AD.
4. Conclusions
Here, we applied genetic, bioinformatic, and functional data to an
algorithm to assess pathogenicity of variants of unknown significance in
APP, PSEN1 and PSEN2. We propose that 19 variants are probable
pathogenic AD mutations. This algorithm was adapted and modified
from a pathogenicity algorithm originally proposed by Guerreiro and
colleagues (Guerreiro et al., 2010a) to impute pathogenicity when ex-
tensive genetic data is missing. We have expanded upon this algorithm
in several important ways: (1) expanding the number of controls in the
association analyses from 100 to 65,000 by leveraging the EVS and
ExAC databases; (2) incorporating cell-based assays to evaluate the
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Fig. 3. Impact of PSEN2 variants of unknown significance on Aβ levels in vitro. A. Diagram of the location of variants of unknown significance in PSEN2. B–C.
Mouse N2A-PS1/PS2 KO cells were transiently transfected with plasmids containing APP WT and PSEN2 WT, known pathogenic mutations (N141I), or a variant of
unknown significance. After 48 h, media was collected and analyzed for Aβ42 and Aβ40 by ELISA. B. Ratio of Aβ42/40 expressed relative to PSEN2 WT. C. Aβ42
(white box) and Aβ40 (gray box) levels expressed relative to PSEN2 WT. Graphs represent mean ± SEM. Significance indicated by Dunnett's t-test (*, p < .05). Red,
known pathogenic mutations. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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bioinformatic functional findings (e.g. conservation between PSEN1 and
PSEN2 and the presence of other mutations at the same residue) in-
dependent of the cell-based functional findings. The cell-based assay
focused on the impact of variants on Aβ42 and Aβ40 levels. Some pa-
thogenic mutations have been reported to lead to reduced Aβ40 and
elevated Aβ43 and Aβ42 (Chavez-Gutierrez et al., 2012). In many of
these mutations, the increase in Aβ43 is much greater than Aβ42
(Chavez-Gutierrez et al., 2012). Because our assays focus on Aβ42 and
Aβ40, we may not capture the magnitude of the aberrant effect on Aβ
levels. Ultimately, definitive pathogenicity comes from segregation:
presence of the variant in multiple family members with autopsy con-
firmed AD and absence in family members free of disease. Designation
of a variant as pathogenic will allow for individuals to enroll in ob-
servational studies and clinical trials for AD, with clear applications in
clinical and research settings.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.nbd.2020.104817.
Declaration of Competing Interest
AMG is a member of the Scientific Advisory Board for Denali
Therapeutics and on the Genetic Scientific Advisory Panel for Pfizer.
The remaining authors declare no competing interests.
Acknowledgments
We thank Carlos Cruchaga for thoughtful discussion of the manu-
script. Funding provided by the NIH: U01AG052411 and Dominantly
Inherited Alzheimer Network (DIAN, UF1AG032438) and the
Washington University-Centene Corporation Personalized Medicine
Initiative.
Fig. 4. APP, PSEN1, and PSEN2 variants that reduce Aβ do not alter total
APP levels. Cells transiently overexpressing WT and risk variants for 48 h were
analyzed by SDS-PAGE and immunoblotting as described in Methods.
Immunoblots were probed with 22C11 (full-length APP; open arrow). The im-
munoblot is representative of 3 replicate experiments.
³
³
Fig. 5. Algorithm to classify variants of unknown significance in APP, PSEN1 and PSEN2 when family segregation data is not available. This model is
modified from the algorithm previously proposed by Guerreiro et al 2010 and Hsu et al., 2018 (Guerreiro et al., 2010a; Hsu et al., 2018) to focus on variants of
unknown significance for which no family segregation data is available. *EVS/ExAC databases should be used to evaluate the presence of a novel variant in the
population. GnomAD contains data from the Alzheimer's Disease Sequencing Project and thus may be enriched for variants that contribute to AD risk.
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